Psithera从Roivant分拆，获4750万美元融资，专注免疫与炎症领域。
Psithera spun out of Roivant with $47.5M and immune, inflammatory focus
生命科学资讯
生物技术与制药领域的最新动态
诺和诺德推出Wegovy口服药；Argenx公司CEO将换人。
Novo launches Wegovy pill; Argenx to swap CEOs
安捷伦科技（NYSE:A）获Evercore ISI上调评级 - MarketBeat
Agilent Technologies (NYSE:A) Upgraded at Evercore ISI - MarketBeat
中国最具创新力的三家制药公司
3 of China’s most innovative pharma companies
Jumpcan Pharmaceutical专利披露新型Nav1.8阻断剂
New Nav1.8 blockers disclosed in Jumpcan Pharmaceutical patent
中国科学家发现新型NMDA与血清素受体拮抗剂
Chinese scientists discover new NMDA and serotonin receptor antagonists
假期通知
Holiday notice
Aktis Oncology拟以1.81亿美元上市，开启行业期待的IPO复苏序幕。
Aktis Oncology eyes $181M listing to start industry’s anticipated IPO rebound
2025年裁员数据：年度裁员轮次同比上升16%
2025 by the numbers: Layoff rounds rise 16% YOY
资金紧张的TME制药失去合作伙伴，促使重新审视眼药战略。
Cash-strapped TME Pharma loses partner, prompting eye drug strategy rethink
Gateway Investment Advisers LLC减持安捷伦科技公司股份 - MarketBeat
Gateway Investment Advisers LLC Decreases Holdings in Agilent Technologies, Inc. $A - MarketBeat
科曼奇公司再获4000万美元，用于测试其先兆子痫siRNA疗法。
Comanche gets $40M more to test its preeclampsia siRNA
施维雅利用Insilico人工智能平台推进早期癌症研发。
Servier taps Insilico’s AI platform for early cancer R&D
Illumina剥离Grail以缓解监管压力，投资者是否需要采取行动？
Should Illumina’s (ILMN) Grail Spinoff to Ease Regulatory Pressure Require Action From Investors? - simplywall.st
诺和诺德推出Wegovy口服药，医保患者月费25美元，自费149美元。
Novo Nordisk launches Wegovy pill at $25 per month for insured patients, $149 cash
2026年上半年值得关注的十项临床试验
10 clinical trials to watch in the first half of 2026
战略诊断测试合作正在加速临床研究进程。
Strategic diagnostic testing partnerships are accelerating clinical research
Cynosure集团有限责任公司出售5,293股赛默飞世尔科技公司股份（代码：$TMO）——MarketBeat报道
Cynosure Group LLC Sells 5,293 Shares of Thermo Fisher Scientific Inc. $TMO - MarketBeat
Teverelix：前列腺癌与泌尿健康治疗新方向
Teverelix: A New Direction in Prostate Cancer and Urologic Health
Insilico香港上市后，与Servier签署潜在价值8.88亿美元癌症研发协议。
Insilico, fresh off its Hong Kong IPO, pens potential $888M cancer R&D pact with Servier